Research Article
Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPARδ Regulation in Hyperlipidemic and Hypertensive Conditions
Figure 8
Schematic illustration for hypothetical reaction mechanisms of fimasartan in nonalcoholic fatty liver disease. Amelioration of nonalcoholic fatty liver disease by fimasartan is mainly accomplished with catabolic activation such as the sequential regulation of PPARδ→ AMPK → PGC-1α. In addition, Aster glehni lowers triglyceride accumulation in liver by inhibiting 11β-HSDH1, ACC, FAS, and TNF-α; also, its effect is additionally exerted by activating adiponectin, MCD, and MCAD. Meaning of symbols: arrow means activation, up and horizontal line means inhibition, and X means blocking.